Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2022-08-30 Annual Report
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Preliminary Final Report - Appendix 4E 25 pages 679.6KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final report for the financial year ended 30 June 2022' and includes detailed financial statements such as consolidated statement of profit or loss and other comprehensive income, and consolidated statement of financial position as at 30 June 2022. It contains comprehensive financial data, management discussion on operations, clinical trial progress, intellectual property, and capital activities. The document is about the full year ended 30 June 2022, indicating it is an annual financial report. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which is a type of annual report. The document is 15,000 characters long, indicating it is a full report, not just an announcement. Therefore, the document fits the definition of an Annual Report (10-K equivalent).
2022-08-30 English
Completion of Second M.A.D. Study for VB0004 2 pages 143.0KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 8 August 2022 from Vectus Biosystems Limited, reporting the completion of a clinical trial cohort (Multiple Ascending Dose study for VB0004). It provides detailed information about the trial progress, safety data, pharmacokinetics, and next steps. The content is an update on clinical trial results and company progress rather than a financial report or regulatory filing. It does not contain financial statements, earnings data, or governance information. It is not a report publication announcement or a certification. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and company development, which does not fit into other specific categories such as earnings release, capital update, or management report.
2022-08-07 English
Quarterly Activities Report & Appendix 4C 7 pages 334.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reports for Australian listed entities. It includes detailed financial data such as cash flow statements, operating activities, investing and financing activities, and cash available for future operations. The document covers the quarter ended 30 June 2022 and contains substantive financial data and analysis, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR). It is not an Annual Report (10-K), Earnings Release (ER), or Regulatory Filing (RNS) because it contains detailed financial statements and operational commentary for a quarter. Therefore, the correct classification is IR with high confidence.
2022-07-28 English
Issue of Shares & Cleansing Notice 1 page 137.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Vectus Biosystems Limited regarding the issuance of shares upon the exercise of options by employees and the expiry of some options following an employee resignation. It includes a Cleansing Notice under section 708A(5)(e) of the Corporations Act 2001, which is a regulatory compliance statement related to the share issue. The document does not contain financial statements or detailed financial analysis but is focused on the issuance of shares and related regulatory disclosures. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not a report publication announcement or a certification, so SHA is appropriate.
2022-07-12 English
Application for quotation of securities - VBS 6 pages 28.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive plan options exercised). This is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather a capital market announcement about securities quotation and issuance. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-07-11 English
Notification of cessation of securities - VBS 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options due to conditions not being met, including specific security codes, quantities, and dates. It is an announcement about changes in the company's issued securities, specifically the cessation of certain securities. The document is relatively short (3829 characters) and does not contain financial statements or detailed financial analysis. It is not a full financial report but rather a regulatory announcement about securities status changes. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-07-11 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.